Krystal Biotech, Inc.

Healthcare · Biotechnology

Overall research band Above average

Quality Above average

Valuation Very weak

Balance sheet Exceptional

Market confirmation Strong

One-minute company read

What this report can tell you now

What the company does

Krystal Biotech, Inc. is a clinical-stage biotechnology company based in Pittsburgh, Pennsylvania, focused on developing redosable gene therapies for severe orphan diseases in the United States. Its lead product candidate, beremagene geperpavec (B-VEC), is in Phase III clinical trials for the treatment of dystrophic epidermolysis bullosa. The company's pipeline includes KB105 for autosomal recessive congenital ichthyosis and KB301 for skin aging, both in Phase I/II trials, as well as preclinical programs such as KB407 for cystic fibrosis and KB104 for Netherton syndrome. Krystal Biotech's customers are patients with rare and severe skin and genetic disorders, and its revenue model is based on the development and potential commercialization of gene therapy treatments.

The current research profile is Mixed Setup, with strong market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC19.0%Model input; read with the evidence status and period context.

Operating margin41.5%Model input; read with the evidence status and period context.

FCF margin48.5%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.